Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007 (Nine months ended September 30, 2007)
Business Overview: Illumina is a leading developer of life science tools for genetic variation analysis. The reporting period is significantly impacted by the January 26, 2007, acquisition of Solexa, Inc., which added next-generation sequencing capabilities to Illumina's portfolio.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2007 |
Nine Months Ended Oct 1, 2006 |
|---|---|---|---|
| Total Revenue | $97,510 | $254,194 | $124,151 |
| Net Income (Loss) | $14,503 | $(274,311) | $22,826 |
| Diluted EPS | $0.24 | $(5.09) | $0.48 |
| Operating Cash Flow | N/A | $44,441 | $30,219 |
| Cash & Short-term Investments | $352,852 | $352,852 | $130,804 |
| Long-term Debt | $400,000 | $400,000 | $0 |
Note: Net loss for the nine months ended September 30, 2007, is primarily driven by a non-cash charge of $303.4 million for acquired in-process research and development (IPR&D) related to the Solexa acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 105% year-over-year for the nine-month period, driven by higher instrument sales (specifically the new Illumina Genome Analyzer) and strong demand for consumables (Infinium products).
- Profitability Impact: While the company was profitable for the quarter ($14.5M net income), the nine-month period resulted in a net loss of $274.3M. This is almost entirely attributable to the $303.4M write-off of Solexa's in-process R&D upon acquisition. Excluding this charge, the company would have reported a net income of approximately $29M for the nine months.
- Balance Sheet Expansion: Total assets grew from $300.6M to $810.2M. Goodwill increased from $2.1M to $249.2M due to the Solexa acquisition.
- Debt Issuance: In February 2007, the company issued $400 million in 0.625% Convertible Senior Notes due 2014. Net proceeds were approximately $390.3 million.
- Stock Repurchases: The company repurchased 7.4 million shares of common stock for approximately $251.6 million during the nine-month period.
Outlook, Risks, and Management Commentary
- Product Launches: Management highlighted the commercial launch of the Illumina Genome Analyzer, BeadXpress System, and new Human DNA Analysis BeadChips as key growth drivers.
- Liquidity: Management anticipates that current cash, cash equivalents, and income from operations will be sufficient to fund operating needs for at least the next twelve months.
- Legal Proceedings (Affymetrix): A significant risk involves ongoing patent litigation with Affymetrix, Inc. A jury found infringement of five patents in March 2007, awarding $16.7 million in retroactive damages. The validity of these patents is being contested in subsequent trial phases scheduled for 2008. The company has not recorded a reserve for this loss as the outcome is uncertain.
- Integration Risks: The company faces risks related to the integration of Solexa's operations, including potential loss of key employees and the complexity of combining two independent companies.
- Margin Pressure: Gross margins decreased slightly (product revenue margin dropped from 68% to 63% for the nine-month period) due to unfavorable product mix and increased non-cash stock-based compensation.
Investor Verification Checklist
- IPR&D Charge: Verify the impact of the $303.4 million non-cash Solexa R&D write-off on the reported net loss and assess pro-forma profitability.
- Affymetrix Litigation: Monitor the status of the second and third phases of the trial regarding patent validity and potential injunctions or increased damages.
- Convertible Notes: Review the terms of the $400M Convertible Senior Notes, specifically the conversion triggers and the associated hedge/warrant transactions.
- Revenue Mix: Analyze the sustainability of revenue growth from the new Genome Analyzer and whether consumable sales will continue to outpace instrument sales.
- Stock-Based Compensation: Assess the impact of increasing stock-based compensation expenses ($24.1M for the nine months) on future operating margins.